<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01008826</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00002015</org_study_id>
    <secondary_id>5P01ES006052</secondary_id>
    <nct_id>NCT01008826</nct_id>
  </id_info>
  <brief_title>Cross-Over Broccoli Sprouts Trial</brief_title>
  <official_title>Cross-Over Broccoli Sprouts Trial - Qidong</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins Bloomberg School of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Qidong Liver Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins Bloomberg School of Public Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis tested is that broccoli sprouts are effective at altering the urinary
      levels of metabolites of the hepatocarcinogen aflatoxin B1 and of the air-borne pollutant
      phenanthrene in residents of Qidong, PRC, where exposures are unavoidable and high. The study
      will evaluate which of two formulations of broccoli sprouts beverage, glucoraphanin-rich or
      sulforaphane-rich, exhibits the best bioavailability and is most effective at modulating the
      biomarkers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary levels of glucoraphanin or sulforaphane and metabolites.</measure>
    <time_frame>Endpoints will be assessed on urine samples collected daily during the intervention.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary levels of aflatoxin-DNA adducts and mercapturic acids as well as mercapturic acids of air-borne pollutants</measure>
    <time_frame>Endpoints will be assessed on urine samples collected daily during the intervention.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>glucoraphanin-rich broccoli extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>sulforaphane-rich broccoli extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>broccoli sprouts extract</intervention_name>
    <description>Glucoraphanin-rich broccoli sprouts extract: 800 micromoles daily for 7 days dissolved in 100 mL of dilute mango juice Sulforaphane-rich broccoli sprouts extract: 150 micromoles daily for 7 days dissolved in 100 mL of dilute mango juice</description>
    <arm_group_label>glucoraphanin-rich broccoli extract</arm_group_label>
    <arm_group_label>sulforaphane-rich broccoli extract</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged 25-65 in good general health with no history of a chronic illness

          -  normal liver function tests (ALT, AST, bilirubin)

          -  normal renal function tests (creatinine, BUN, urinalysis)

          -  serum alpha-fetoprotein negative

        Exclusion Criteria:

          -  personal history of cancer, except for non-melanoma skin cancer

          -  use of prescribed medications

          -  hepatomegaly by clinical exam

          -  unwillingness to avoid cruciferous vegetable consumption for the duration of the study

          -  for women, a positive pregnancy test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas W Kensler, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Qidong Liver Cancer Institute</name>
      <address>
        <city>Qidong</city>
        <state>Jiangsu</state>
        <zip>226200</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2009</study_first_submitted>
  <study_first_submitted_qc>November 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2009</study_first_posted>
  <last_update_submitted>September 15, 2011</last_update_submitted>
  <last_update_submitted_qc>September 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins Bloomberg School of Public Health</investigator_affiliation>
    <investigator_full_name>Thomas Kensler</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>sulforaphane</keyword>
  <keyword>pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulforafan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

